MannKind at neutral by Merrill

Merrill Lynch analyst Hari Sambasivam gave MannKind Corp. a neutral rating on news that the company presented its phase 3 data for Technosphere Insulin (TI; an inhaled insulin) at the European Association for the Study of Diabetes in Copenhagen. Treatment with TI was not associated with any change in lung function. While the analyst views this data as positive, the two-year data will be needed to confirm the results. If the comparable efficacy, pulmonary safety and absence of weight gain are confirmed in longer-term studies, Technosphere Insulin could have significant revenue potential, the analyst said. Shares of the Valencia, Calif.-based biopharmaceutical company were up 11 cents, or 0.57%, at $19.39. (Nasdaq: MNKD)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.